New Users Registration  |  Useful Links  |  FAQ  |  Site Map 
 
Go Search

 

Skip Navigation LinksHealth Xchange > News
  News  
  Categories  
     
  Chronology  
 
  2013 2014   Dec 2014 | Nov 2014 | Oct 2014 | Sep 2014 | Aug 2014 | Jul 2014 | Jun 2014 | May 2014 | Apr 2014 | Mar 2014 | Feb 2014 | Jan 2014 |
  2013   Dec 2013 | Nov 2013 | Oct 2013 | Sep 2013 | Aug 2013 | Jul 2013 | Jun 2013 | May 2013 | Apr 2013 | Mar 2013 | Feb 2013 | Jan 2013 |
  2012   Dec 2012 | Nov 2012 | Oct 2012 | Sep 2012 | Aug 2012 | Jul 2012Jun 2012May 2012Apr 2012Mar 2012 | Feb 2012 | Jan 2012 |
  2011   Dec 2011Nov 2011Oct 2011 | Sep 2011 | Aug 2011Jul 2011Jun 2011 | May 2011 | Apr 2011 | Mar 2011 | Feb 2011 | Jan 2011 |
  2010   Dec 2010 | Nov 2010 | Oct 2010 | Sep 2010 | Aug 2010 | Jul 2010 | Jun 2010 | May 2010 | Apr 2010 | Mar 2010 | Feb 2010 | Jan 2010 |
  2009   Dec 2009 | Nov 2009 | Oct 2009 | Sep 2009 | Aug 2009 |
 
     
  Topic  
 
  Health Policy and Announcements | Diseases and Outbreaks
  Medical Research | New Treatments and Technology
   
 
     
  RSS  
 
  Singapore   SingHealth | Health Promotion Board | Ministry of Health | Asiaone
  International   World Health Organization | Centre for Disease Control and Prevention (US)
       
 
     
  News Article  
 

Tiger Balm and Kwan Loong Oil safe for use

 
  Friday, 13 l 08 l 2010 Source:  The Straits Times   
By: Lee Hui Chieh
     
 

TIGER Balm and Kwan Loong Oil – medicated ointments meant for pain relief – are safe for use, despite
a warning letter issued recently to their maker by the United States drug regulator.

The Health Sciences Authority (HSA) said yesterday that it did not have any major safety concerns about the products, based on its assessment of the available information. Nor has it received reports of anyone reacting adversely to them.

Their safety came into question after the US Food and Drug Administration (FDA) issued a warning letter to their maker, Singapore-based Haw Par Healthcare, following an inspection of its manufacturing facility here in October last year.

In the letter dated July 20, the FDA said it had found that the tests used on Tiger Balm and Kwan Loong Oil were inadequate to detect potential impurities, that laboratory test records were incomplete, and control procedures were not followed.

The Tiger Balm Pain Relieving Patch was also labelled and branded incorrectly, it added.

Noting that countries vary in categorising and regulating health products, the HSA said that the FDA’s letter highlighted technical deficiencies that Haw Par needs to resolve to meet the FDA’s requirements for marketing the products in the US.

The HSA does not require medicated balms and oils to be licensed, because they are considered lower-risk products than medicines. Tiger Balm and Kwan Loong Oil do not contain potent medicinal ingredients
and are applied externally, it said.

But the HSA does require such products to comply with safety and quality requirements, for example, in not containing any toxins.

Haw Par Healthcare said that its manufacturing facility has been inspected and passed by Germany, Japan and Britain. The labelling of its pain relieving patch, which has been sold in the US since 1998, also adheres to the guidelines of the various countries where the patch is sold, it noted. It is working with the FDA to resolve the concerns, it said.

     
  Ask the Specialists - Free Doctor Q&A
(Now - 31st Jul)
 
    Stress and Anxiety
If you have questions on stress and anxiety, take this opportunity to ask our specialist today.
 
    Previous Q&As
Check out our archive for all our previous doctor's Q&As!
*Latest Update: About LASIK
 
e-Appointment Online
Health Buddy App